C4 ditches its EGFR degrader
Not long after BeOne deprioritised an EGFR degrader, C4 Therapeutics has discontinued development of its contender, CFT8919, outside China, it said during its first-quarter earnings on Tuesday. CFT8919 had been designed selectively to degrade EGFR with the L858R mutation, while sparing wild-type EGFR. In China the asset is licensed to Betta Pharmaceuticals, under a 2023 deal worth $10m up front. A Betta-sponsored Chinese phase 1 is listed on clinicaltrials.gov, and C4 previously said it would use data from this to inform potential ex-China clinical development, with a decision due by the end of the first quarter 2026. It seems that the results didn’t justify C4 moving forward. Meanwhile, BeOne recently deprioritised its rival asset BG-60366, which had previously looked in trouble after that company downsized its phase 1 trial. That project was said to hit a broad range of EGFR mutations. These recent moves leave only three remaining EGFR degraders in the clinic, according to OncologyPipeline – all being developed in China. Little information is available on Haisco's HSK40118, while Jing Medicines’ HJ-004-02 is designed to target classical, rare and exon 20 insertion mutations, and its HJ-002-03 is described as a Protac degrader against common, rare and resistance mutations.
Clinical-stage EGFR degraders
| Project | Company | Mechanism of action | Status |
|---|---|---|---|
| Still active | |||
| HSK40118 | Haisco Pharmaceutical | EGFR mutant degrader | China phase 1 in NSCLC ongoing |
| HJ-004-02 | Jing Medicine Technology | EGFR mutant degrader | China phase 1 in NSCLC ongoing |
| HJ-002-03 | Jing Medicine Technology | EGFR mutant Protac | China phase 1 in NSCLC ongoing |
| Fallen by the wayside | |||
| CFT8919 | C4 Therapeutics | EGFR L858R degrader | Discontinued outside China May 2026 |
| BG-60366 | BeOne | EGFR mutant degrader | Deprioritised May 2026 |
Source: OncologyPipeline & company releases.
143
